Published in Biotech Business Week, July 6th, 2009
"Blood from consented volunteers was drawn into 3.2% citrate (9:1 v/v) and either used immediately or centrifuged to obtain platelet-poor plasma. Increasing concentrations of aptamer (6-24 mu g/ml) alone or in combination with heparin (0.1 U/ml) or lepirudin (0.2 mu g/ml) were added to blood and plasma samples. Activated clotting times (ACT+, low...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.